| The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic V Namasivayam, M Vanangamudi, VG Kramer, S Kurup, P Zhan, X Liu, ... Journal of medicinal chemistry 62 (10), 4851-4883, 2018 | 140 | 2018 |
| Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I A Gangjee, HD Jain, S Kurup Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2007 | 92 | 2007 |
| Dihydrofolate reductase as a target for chemotherapy in parasites A Gangjee, S Kurup, O Namjoshi Current pharmaceutical design 13 (6), 609-639, 2007 | 82 | 2007 |
| Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II A Gangjee, HD Jain, S Kurup Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2008 | 77 | 2008 |
| Synthesis and biological activity of N4-phenylsubstituted-6-(2, 4-dichloro phenylmethyl)-7H-pyrrolo [2, 3-d] pyrimidine-2, 4-diamines as vascular endothelial growth factor … A Gangjee, S Kurup, MA Ihnat, JE Thorpe, SS Shenoy Bioorganic & medicinal chemistry 18 (10), 3575-3587, 2010 | 64 | 2010 |
| Design, synthesis and biological activity of N4-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth … S Kurup, B McAllister, P Liskova, T Mistry, A Fanizza, D Stanford, ... Journal of enzyme inhibition and medicinal chemistry 33 (1), 74-84, 2018 | 30 | 2018 |
| Non-nucleoside reverse transcriptase inhibitors (NNRTIs): A brief overview of clinically approved drugs and combination regimens M Vanangamudi, S Kurup, V Namasivayam Current opinion in pharmacology 54, 179-187, 2020 | 27 | 2020 |
| N4-Aryl-6-substitutedphenylmethyl-7H-pyrrolo [2, 3-d] pyrimidine-2, 4-diamines as receptor tyrosine kinase inhibitors A Gangjee, S Kurup, MA Ihnat, JE Thorpe, B Disch Bioorganic & medicinal chemistry 20 (2), 910-914, 2012 | 21 | 2012 |
| Synthesis of 5, 7-disubstituted-4-methyl-7H-pyrrolo [2, 3-d] pyrimidin-2-amines as microtubule inhibitors A Gangjee, S Kurup, CD Smith Bioorganic & medicinal chemistry 21 (5), 1180-1189, 2013 | 8 | 2013 |
| Three-Dimensional Visualization of Kinase Inhibitors as Therapeutically Relevant Examples To Reinforce Types of Enzyme Inhibitors S Kurup, P Sakharkar Journal of Chemical Education 96 (2), 296-303, 2019 | 3 | 2019 |
| A team-based assignment to integrate basic science and pharmacotherapeutic principles for anticancer agents S Kurup, P Jungsuwadee, P Sakharkar American Journal of Pharmaceutical Education 81 (5), 93, 2017 | 3 | 2017 |
| Comparing efficacy of erlotinib and bevacizumab combination with erlotinib monotherapy in patients with advanced non-small cell lung cancer (NSCLC): A systematic review and … P Sakharkar, S Kurup Diseases 11 (4), 146, 2023 | 2 | 2023 |
| A Team‐based Assignment to Integrate Basic Science and Pharmacotherapeutic Principles for Anticancer Agents P Jungsuwadee, P Sakharkar, S Kurup The FASEB Journal 31, 660.1-660.1, 2017 | 1 | 2017 |
| Kinase inhibition as a therapeutic approach for P. falciparum malaria S Kurup Malar Cont Elimination 4, e131, 2015 | 1 | 2015 |
| Drugs to treat head and neck cancers: mechanisms of action S Kurup, KE Dineley, LM Malaiyandi, R Adewuya, LA Potempa Head & Neck Cancer: Current Perspectives, Advances, and Challenges, 861-913, 2013 | 1 | 2013 |
| Novel analogs of 4-substituted pyrrolo[2,3-d]pyrimidines as dual-targeted mEGFR/AURKA inhibitors for lung cancer S Kurup, G Carpenter, S Satawa, F Amissah, E Lisabeth, M Giletto, ... Cancer Research 84 (6_Supplement), 4474-4474, 2024 | | 2024 |
| Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis P Sakharkar, S Kurup, S Deb, K Assaad, D Gesinski, EJ Gayle Cancers 16 (6), 1188, 2024 | | 2024 |
| Design, synthesis, and evaluation of dual EGFR/AURKB inhibitors as anticancer agents for non-small cell lung cancer S Kurup, D Gesinski, K Assaad, A Reynolds Bioorganic & Medicinal Chemistry Letters 100, 129612, 2024 | | 2024 |
| Substituted pyrrolo [2, 3-d] pyrimidines and pyrazolo [3, 4-d] pyrimidines as inhibitors for multi-resistant cancers SRK Kurup US Patent 11,814,388, 2023 | | 2023 |
| Design, synthesis and evaluation of dual-targeted mEGFR and AURK inhibitors as anticancer agents D Gesinski, S Kurup Cancer Research 83 (7_Supplement), 5337-5337, 2023 | | 2023 |
